Citation

Larkin GL, Beautrais AL, Lippmann M. Inj. Prev. 2010; 16(Suppl 1): A260.

Copyright

(Copyright © 2010, BMJ Publishing Group)

DOI

10.1136/ip.2010.029215.925

PMID

unavailable

Abstract

Safety 2010 World Injury Conference, London, Abstract: : Background Suicidal behaviour is a pervasive and pressing public health burden. Emergency Departments (EDs) visits for mood disorders in general, and for major depression, suicidal ideation, and suicide attempts in particular, have increased in the last 15 years, showing no sign of declining. Intervening with effective treatments in the ED when suicidal patients are accessible could achieve a more rapid, effective and safe disposition. At present there is a dearth of effective ED treatments for acutely suicidal and depressed patients. A single sub-anaesthetic dose of IV ketamine can rapidly reduce depressive symptoms in treatment-resistant depressed (TRD) patients, with anti-depressant responses detected within 1-2 h postinfusion and maintained in a majority of patients for 1-7 days, without significant adverse side effects. To date, research has focused on the potential of ketamine to treat TRD.

Method Pilot study to assess the feasibility of administering low-dose ketamine in the ED as a rapidly acting anti-depressant which alleviates the intensity of suicide ideation, as well as improving depressed mood.

Results 20 ED patients with a primary presenting complaint of suicide ideation or who have made a suicide attempt were administered single sub-anaesthetic dose of either ketamine (0.25 mg/kg IV bolus over 3 min). Ketamine rapidly reduced both suicide ideation and depressive symptoms.

Conclusions These results suggest the exploratory research findings of a low dose of ketamine can be translated from TRD patients to the clinical setting of the ED for suicidal patients.